Odyssey Health reports $5.73M net loss for FY 2026

Annual report, 3 new risk factors

Written from the 10-K on EDGAR. Check the filing before you rely on it.

What changed since last year

3 new risk factors · 10 removed

Compared with the 10-K for the period ended Jul 31, 2025.

New risk factors (3)

maturing on January 31, 2027 that we do not have the funds to repay, and the waivers we have received from our principal noteholder are limited. +12 more paragraphs
$12,277,546, current assets of $147,859, and a working capital deficit of $12,129,687. These factors raise substantial doubt about our ability to continue as a going concern which is dependent on our ability to raise the required additional capital or debt financing to meet short and long-term operating requirements… +2 more paragraphs
OTCQB and is now quoted on the OTCID Basic Market, which may reduce liquidity and adversely affect our stock price. Our common stock could also be moved to a lower market tier or to the Expert Market. +8 more paragraphs

Removed risk factors (10)

attract, integrate, retain and motivate qualified management and sales personnel;
$7,004,421, current assets of $49,723, and a working capital deficit of $6,954,698. These factors raise substantial doubt about our ability to continue as a going concern which is dependent on our ability to raise the required additional capital or debt financing to meet short and long-term operating requirements. We…
be subject to claims or lawsuits. These lawsuits may result in significant legal fees and expenses and could divert management s time and other resources. If the claims contained in these lawsuits are successfully asserted against us, we could be liable for damages and be required to alter or cease portions of our…
could subject us to significant liabilities, require us to cease using the subject technology or require us to license the subject technology from the third party, all of which could have a material adverse effect on our business.
are required to submit an Investigational New Drug Application, or IND, the contents of which are subject to discussions with the FDA and include, among other things, results of preclinical studies and other testing, manufacturing information, proposed clinical trial protocols and a general investigational plan. We…
and 5 more in the filing

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.